Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

This study tests a combination of three drugs — venetoclax, olverembatinib (a BCR-ABL inhibitor), and prednisone — for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL), a type of fast-growing blood cancer. **You may be eligible if...** - You are 18 or older - You have a new diagnosis of Philadelphia chromosome-positive B-cell ALL (confirmed by genetic testing) - You are in good enough health to participate (ECOG 0–2) with expected survival of at least 3 months - Your organ function is within required ranges **You may NOT be eligible if...** - Your leukemia is an advanced-stage chronic myeloid leukemia (accelerated phase or blast crisis) - Your leukemia has spread to the brain or spinal fluid - You have had prior systemic anti-leukemia treatment (other than allowed pre-treatment) - You had a heart attack within the past 12 months or have significant heart disease Talk to your doctor to see if this trial is right for you.